Our paper suggests that momordicine I at nontoxic concentrations (0.1–1 μM) effectively attenuates the profibrogenic TGF-β1-Smad2/3 signaling pathway and is thus an effective therapy for diabetes-associated cardiac fibrosis. The gene discussed is SMAD2; the disease is diabetes mellitus.